FCA Suits Over Poor Drug Quality Are Down But Not Out
Law360, New York (February 28, 2014, 5:17 PM EST) -- The Fourth Circuit's new ruling that sloppy drugmaking can't support False Claims Act cases is the latest blow to lawsuits that equate regulatory noncompliance with fraud, but experts say whistleblowers and prosecutors may still be able to successfully target manufacturers that have egregious quality-control lapses.
In its recent decision, the appeals court flatly rejected the idea that billing the government for impure medications can by itself give rise to FCA liability. All that's required for coverage by Medicare and Medicaid is approval by the U.S. Food and Drug Administration, and nothing bars those programs from paying for medicines that aren't of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!